Below are the top 10 Pharmaceutical stocks with highest upside potential, UPDATED TODAY before 4:30 AM ET, based on the difference between current price and Wall Street analysts' average target price. One Chinese company (CBP) is on the list.
Marina Biotech, Inc. (NASDAQ:MRNA) has the 1st highest upside potential in this segment of the market. Its upside is 316.7%. Its consensus target price is $2.83 based on the average of all estimates. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) has the 2nd highest upside potential in this segment of the market. Its upside is 294.7%. Its consensus target price is $6.00 based on the average of all estimates.Cardium Therapeutics Inc. (AMEX:CXM) has the 3rd highest upside potential in this segment of the market. Its upside is 294.7%. Its consensus target price is $1.50 based on the average of all estimates. DARA BioSciences, Inc. (NASDAQ:DARA) has the 4th highest upside potential in this segment of the market. Its upside is 273.4%. Its consensus target price is $11.58 based on the average of all estimates.Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) has the 5th highest upside potential in this segment of the market. Its upside is 257.1%. Its consensus target price is $4.75 based on the average of all estimates.
CytRx Corporation (NASDAQ:CYTR) has the 6th highest upside potential in this segment of the market. Its upside is 244.9%. Its consensus target price is $3.00 based on the average of all estimates. PharmAthene, Inc. (AMEX:PIP) has the 7th highest upside potential in this segment of the market. Its upside is 220.7%. Its consensus target price is $11.00 based on the average of all estimates. AVANIR Pharmaceuticals (NASDAQ:AVNR) has the 8th highest upside potential in this segment of the market. Its upside is 218.3%. Its consensus target price is $12.00 based on the average of all estimates. GenVec, Inc. (NASDAQ:GNVC) has the 9th highest upside potential in this segment of the market. Its upside is 192.1%. Its consensus target price is $1.13 based on the average of all estimates. Renhuang Pharmaceuticals, Inc. (AMEX:CBP) has the 10th highest upside potential in this segment of the market. Its upside is 190.5%. Its consensus target price is $4.88 based on the average of all estimates.
No comments:
Post a Comment